Announcements Trials
Browse Landscape

Status

Approved for marketing 1

Sponsor Class

INDUSTRY 1

Study Type

Expanded_access 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Ovarian Neoplasms 20Breast Neoplasms 11Prostatic Neoplasms 10Neoplasms 7Neoplasm Metastasis 7Fallopian Tube Neoplasms 7Pancreatic Neoplasms 6Endometrial Neoplasms 5Triple Negative Breast Neoplasms 4Lung Neoplasms 3Head and Neck Neoplasms 3Glioblastoma 3Carcinoma, Ovarian Epithelial 3Small Cell Lung Carcinoma 2Prostatic Neoplasms, Castration-Resistant 2Glioma 2Carcinoma, Non-Small-Cell Lung 2Brain Neoplasms 2Biliary Tract Neoplasms 2Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Unilateral Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Sarcoma 1SCLC,Extensive Stage 1Recurrence 1Rectal Neoplasms 1Prostate Adenocarcinoma 1

Interventions

olaparib 4Pluvicto 4Abiraterone Acetate 4Prednisone 3Prednisolone 3testosterone 17 beta-cypionate 2radium Ra 223 dichloride 2enzalutamide 2darolutamide 2Docetaxel 2Androgen Antagonists 2sipuleucel-T 1niraparib 1lactitol 1fludarabine phosphate 1fludarabine 1fluciclovine F-18 1enfortumab vedotin 1cabozantinib 1cabazitaxel 1alovudine 1abiraterone 1Standard of Care 1Radium-223 1PSMA-617 1Nivolumab 1Gonadotropin-Releasing Hormone 1Cyclophosphamide 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Castration-resistant Prostate Cancer × niraparib × 1 year × Clear all
NCT05401214 2025-06-13

Pre-approval Access Single Patient Request for Niraparib / Abiraterone Acetate Combination (Nira/AA Combination)

Janssen Research & Development, LLC

Approved for marketing
Genitourinary

Metastatic Castration-resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡